Skip to content

Depression: all studies

Page 632 of 1,035: studies 6,311 to 6,320 of 10,348, newest first. Back to the depression overview

Research

The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.

Psychedelic Medicine September 1, 2024 Banan Ramarushton, Heidemarie Blumenthal, Anthony Ryals et al. 2 citations

Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination...

DOI: 10.1089/psymed.2024.0009 (opens in new tab) Full text (opens in new tab) Psychedelics Repetitive negative thinking Rumination

Nurses' Perceptions of Psychedelics to Address Mental Health Problems in the United States.

Psychedelic Medicine September 1, 2024 Carolyn M. Porta, Madison E. Weirick, Anna Graefe et al. 4 citations

To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected through an anonymous e-survey of Minnesota registered nurses, advanced practice registered nurses, and psychiatric-mental health nurse practitioners in Spring 2023; the pool was randomly selected from the Minnesota Board of Nursing registry. A total...

Effect of esketamine combined with pregabalin on acute postsurgical pain in patients who underwent resection of spinal neoplasms: a randomized controlled trial.

Pain September 1, 2024 Yang Zhou, Wanchen Sun, Yuxuan Fu et al. 9 citations

Moderate-to-severe acute postsurgical pain (APSP) can prolong the recovery and worsen the prognosis of patients who undergo spinal surgery. Esketamine and pregabalin may resolve APSP without causing hyperpathia or respiratory depression after surgery. However, there are other risks, such as dissociative symptoms. We designed a randomized controlled trial to investigate the effect of the...

DOI: 10.1097/j.pain.0000000000003211 (opens in new tab) Full text (opens in new tab) Pain-management Spine-surgery Clinical-research Anesthesia +1

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).

Journal of Affective Disorders September 1, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 8 citations

Ketamine and esketamine have been proven to be effective in treating adults with treatment resistant depression (TRD). Preliminary evidence indicates that, when combined with behavioral and psychological interventions, both agents may offer benefits for individuals with substance use disorder (SUD) and alcohol use disorder (AUD). Notwithstanding, concerns have been raised as to whether either...

DOI: 10.1016/j.jad.2024.05.116 (opens in new tab) Full text (opens in new tab) Diversion Ketamine abuse liability Treatment-resistant depression trd Adverse event reporting +2

Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.

Neuropharmacology September 1, 2024 Devin P Hagarty, Adam Dawoud, Alfonso Brea Guerrero et al. 6 citations

Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant Depression patients and repeated infusions are required to sustain its antidepressant properties. However, KET is an addictive drug, and so more preclinical and clinical research is needed to assess the safety of recurring treatments in both sexes....

DOI: 10.1016/j.neuropharm.2024.110008 (opens in new tab) Full text (opens in new tab) Dose-response Sex differences Cfos Addiction-risk +3

Role of oxidative phosphorylation in the antidepressant effects of arketamine via the vagus nerve-dependent spleen-brain axis.

Neurobiology of Disease September 1, 2024 Lijia Chang, Yan Wei, Youge Qu et al. 22 citations

Arketamine, the (R)-enantiomer of ketamine, exhibits antidepressant-like effects in mice, though the precise molecular mechanisms remain elusive. It has been shown to reduce splenomegaly and depression-like behaviors in the chronic social defeat stress (CSDS) model of depression. This study investigated whether the spleen contributes to the antidepressant-like effects of arketamine in the CSDS...

DOI: 10.1016/j.nbd.2024.106573 (opens in new tab) Full text (opens in new tab) Arketamine Oxidative phosphorylation Spleen-brain axis Vagus nerve +5

Entactogen Effects of Ketamine: A Reverse-Translational Study.

American Journal of Psychiatry September 1, 2024 Evan M. Hess, Dede Greenstein, Olivia L Hutchinson et al. 12 citations

The authors sought to assess the prosocial, entactogen effects of ketamine. Pleasure from social situations was assessed in a sample of participants with treatment-resistant depression from randomized, double-blind, placebo-controlled studies, using four items of the Snaith-Hamilton Pleasure Scale (SHAPS) at five time points over 1 week following treatment with ketamine (0.5 mg/kg...

DOI: 10.1176/appi.ajp.20230980 (opens in new tab) Full text (opens in new tab) Depressive disorders Entactogens Ketamine/esketamine #ketamine ketamine therapy +6

Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.

Journal of veterinary science September 1, 2024 Sun Mi Gu, Eunchong Hong, Sowoon Seo et al. 1 citation

Glutamic acid decarboxylase 67 (GAD67) is a gamma-aminobutyric acid (GABA) synthesis enzyme associated with the function of other neurotransmitter receptors, such as the N-methyl-D-aspartate (NMDA) receptor and cannabinoid receptor 1. However, the role of GAD67 in the development of different abused drug-induced reward behaviors remains unknown. In order to elucidate the mechanisms of substance...

DOI: 10.4142/jvs.23325 (opens in new tab) Full text (opens in new tab) Gad67 Jwh-018 Conditioned place preference Gamma-aminobutyric acid +5

Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science.

Journal of Studies on Alcohol and Drugs September 1, 2024 Brian Rush, Olivia Marcus, Sara García et al. 12 citations

This article focuses on the outcomes at 1 year post-treatment of a naturalistic evaluation of services provided through the Takiwasi Centre, an accredited Peruvian therapeutic community offering an ayahuasca-assisted, integrative treatment program for addiction rehabilitation. Participants (n = 52) completed structured interviews and a battery of validated instruments. Outcome measures included...

DOI: 10.15288/jsad.23-00005 (opens in new tab) Full text (opens in new tab) Addiction-treatment Psychedelic-therapy Ayahuasca-healing Alternative-medicine +1

Stutterers' experiences on classic psychedelics: A preliminary self-report study.

Journal of Fluency Disorders September 1, 2024 Eric S. Jackson, Noam Goldway, Hope Gerlach-Houck et al. 4 citations

Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects are often limited. Pharmaceutical treatments have been explored but there are no FDA-approved treatments for stuttering. Interest has grown in the potential use of classic psychedelics, including psilocybin and LSD, which have shown effectiveness in...